Elevated levels of Cyclin D1b could function as a novel biomarker of lethal metastatic disease in prostate cancer patients, according to a pre-clinical study published in the Journal of Clinical Investigation by researchers at the Kimmel Cancer Center at Jefferson. Read more here.
Study mentioned: Augello MA, et al. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest. 2012 Dec 21. [Epub ahead of print] PMID: 23257359
No comments:
Post a Comment